Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence

Markers of prostate tumor recurrence after radical prostatectomy are lacking and highly demanded. The androgen receptor (AR) is a nuclear receptor that plays a pivotal role in normal and cancerous prostate tissue. AR interacts with a number of proteins modulating its stability, localization, and activity. To test the hypothesis that an increased expression of AR partners might foster tumor development, we immunopurified AR partners in human tumors xenografted into mice. One of the identified AR partners was the multifunctional enzyme carbamoyl‐phosphate synthetase II, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyzes the 3 initial steps of pyrimidine biosynthesis. We combined experiments in C4‐2, LNCaP, 22RV1, and PC3 human prostate cell lines and analysis of frozen radical prostatectomy samples to study the CAD‐AR interaction. We show here that in prostate tumor cells, CAD fosters AR translocation into the nucleus and stimulates its transcriptional activity. Notably, in radical prostatectomy specimens, CAD expression was not correlated with proliferation markers, but a higher CAD mRNA level was associated with local tumor extension (P= 0.049) and cancer relapse (P=0.017). These results demonstrate an unsuspected function for a key metabolic enzyme and identify CAD as a potential predictive marker of cancer relapse.—Morin, A., Fritsch, L., Mathieu, J. R. R., Gilbert, C., Guarmit, B., Firlej, V., Gallou‐Kabani, C., Vieillefond, A., Delongchamps, N. B., Cabon, F. Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J. 26, 460–467 (2012). www.fasebj.org

[1]  K. Knudsen,et al.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.

[2]  R. Kodet,et al.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIα, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma , 2010, Virchows Archiv.

[3]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. , 2009, European urology.

[4]  A. Harel-Bellan,et al.  Physical and Functional Interaction between Heterochromatin Protein 1α and the RNA-binding Protein Heterogeneous Nuclear Ribonucleoprotein U* , 2009, The Journal of Biological Chemistry.

[5]  D. Tindall,et al.  Androgen modulation of coregulator expression in prostate cancer cells. , 2009, Molecular endocrinology.

[6]  Nigel Borley,et al.  Prostate cancer: diagnosis and staging. , 2009, Asian journal of andrology.

[7]  P. Braun,et al.  Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. , 2008, Asian journal of andrology.

[8]  P. Hodor,et al.  Interaction between the Androgen Receptor and RNase L Mediates a Cross-talk between the Interferon and Androgen Signaling Pathways* , 2005, Journal of Biological Chemistry.

[9]  Frederic D Sigoillot,et al.  Nuclear Localization and Mitogen-activated Protein Kinase Phosphorylation of the Multifunctional Protein CAD* , 2005, Journal of Biological Chemistry.

[10]  G. Bartsch,et al.  Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. , 2005, Endocrine-related cancer.

[11]  R. Bouvier,et al.  Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. , 2005, Cancer research.

[12]  Frederic D Sigoillot,et al.  Breakdown of the regulatory control of pyrimidine biosynthesis in human breast cancer cells , 2004, International journal of cancer.

[13]  T. Tammela,et al.  Expression of Androgen Receptor Coregulators in Prostate Cancer , 2004, Clinical Cancer Research.

[14]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[15]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[16]  S. Safe,et al.  Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. , 2003, Endocrinology.

[17]  V. Ogryzko,et al.  Immunoaffinity purification of mammalian protein complexes. , 2003, Methods in enzymology.

[18]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[19]  G. Wilding,et al.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[21]  E. Mucciolo,et al.  Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole. , 1995, Anticancer research.

[22]  B H Margolin,et al.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Evans,et al.  Intracellular location of the multidomain protein CAD in mammalian cells , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  J. Dixon,et al.  Increased messenger RNA concentration for carbamoyl-phosphate synthase II in hepatoma 3924A. , 1987, Biochemical and biophysical research communications.

[25]  J. Karle,et al.  Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. , 1984, The Journal of biological chemistry.

[26]  G. Stark,et al.  Purification from hamster cells of the multifunctional protein that initiates de novo synthesis of pyrimidine nucleotides. , 1977, The Journal of biological chemistry.